Ra Pharma’s Cyclomimetic Technology To Help Merck With Difficult Targets
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first partnership, Ra, focused on solutions for intracellular protein-protein reactions, could earn up to $200 million by helping Merck to discover and develop drug candidates for protein targets in several undisclosed therapeutic areas.
You may also be interested in...
Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.